Humacyte, Inc. $HUMA Shares Acquired by UBS Group AG

UBS Group AG boosted its stake in Humacyte, Inc. (NASDAQ:HUMA) by 48.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,978,610 shares of the company’s stock after purchasing an additional 976,275 shares during the period. UBS Group AG’s holdings in Humacyte were worth $2,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Truist Financial Corp acquired a new stake in Humacyte in the third quarter worth $28,000. Financial Advisors Network Inc. acquired a new stake in Humacyte in the second quarter worth $28,000. Prudential Financial Inc. acquired a new stake in Humacyte in the second quarter worth $28,000. Equitable Holdings Inc. acquired a new stake in Humacyte in the third quarter worth $29,000. Finally, Imprint Wealth LLC acquired a new stake in Humacyte in the third quarter worth $33,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Humacyte

In other Humacyte news, Director Kathleen Sebelius purchased 56,818 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $0.88 per share, with a total value of $49,999.84. Following the completion of the purchase, the director owned 148,025 shares in the company, valued at $130,262. This trade represents a 62.30% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dale A. Sander sold 45,887 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. The trade was a 14.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on HUMA shares. Wall Street Zen raised Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. BTIG Research dropped their target price on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.57.

Humacyte Stock Performance

NASDAQ:HUMA opened at $1.05 on Tuesday. Humacyte, Inc. has a 1 year low of $0.55 and a 1 year high of $2.93. The stock has a market cap of $233.12 million, a price-to-earnings ratio of -1.84 and a beta of 2.31. The business has a fifty day moving average of $0.83 and a 200-day moving average of $1.03. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.46 million. Equities analysts predict that Humacyte, Inc. will post -0.32 earnings per share for the current year.

Humacyte Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.